The United Arab Emirates Department of Health and Prevention (MoHAP) has approved the emergency use of a new recombinant protein vaccine for Sinopharm CNBG.
The new vaccine will be manufactured and distributed by Hayat Biotech, a joint venture between G42 and Sinopharm CNBG.
It will be open to the public as a booster effect from January 2022.
According to the state news agency WAM, approval was granted after rigorous monitoring and evaluation of data from surveys conducted in the UAE.
This study included individuals who had been vaccinated twice with the inactivated vaccine for Sinopharm CNBG.
The seroconversion rate was up to 100% of neutralizing antibodies, was highly safe, and no side effects were recorded for all participants.
The ministry added that the vaccine has shown improved immunity to SARS-CoV-2 mutants, is safer, and enables rapid production and easy storage and distribution.
A study based in the United Arab Emirates also showed an immune response to a new variant of the virus in volunteers who had previously been vaccinated twice with the inactivated vaccine for Sinopharm CNBG.
The ministry said the emergency use of the new vaccine is fully compliant with regulations and laws for a faster review of the licensing process.
On Monday, the Ministry of Health confirmed that 20,492 doses of the approved Covid-19 vaccine had been administered in the last 24 hours.
To date, the total doses provided are 22,506,696 and the vaccine distribution rate is 227.56 per 100 people.
Also on Monday, the ministry reported 1,732 new infections in the last 24 hours.
https://gulfbusiness.com/uae-approves-new-sinopharm-vaccine-to-be-used-as-booster-jabs/ United Arab Emirates Approves New Sinopharm Vaccine Used as Booster Jab